News Releases

December 8, 2017
Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver Disorders
Partnership Integrates Living Medicine Drug Discovery and Development Expertise with Leading Industrial-Scale Organism Engineering Applied to Therapeutics for the First Time Companies Aim to Expand Portfolio of Novel, Probiotic-Based, Living Medicines with Additional Partners BOSTON & CAMBRIDGE,...
November 13, 2017
Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress
- Reported Positive Top-line Results from Phase 1 Clinical Study of SYNB1020 in Healthy Volunteers - - Received Orphan Drug Designation for SYNB1618, a Synthetic Biotic TM Medicine for the Treatment of Phenylketonuria - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2017-- Synlogic, Inc....
November 8, 2017
Synlogic to Present at Upcoming Investor Conferences in November
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present at the following conferences in November: The Stifel 2017 Healthcare Conference at 11:45 am ET on November 15 th...
November 8, 2017
Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia
- SYNB1020 Oral Treatment Resulted in a Significant Dose-Dependent Effect on a Plasma Nitrogen Endpoint Demonstrating Mechanistic Activity - - Data Support Initiation of Two Phase 1b/2a Studies in 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Synlogic, Inc .,( Nasdaq:SYBX ) a...
October 24, 2017
Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2017-- Synlogic ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to SYNB1618,...
October 10, 2017
Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 10, 2017-- Synlogic ( Nasdaq: SYBX ) announced the addition of two experienced executives to key leadership roles: Andrew Gengos as Chief Operating Officer and Head of Corporate Development, and Adam Thomas as Chief Human Resources Officer....
September 20, 2017
Synlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Synlogic’s president and chief executive officer, will present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology at 4:00 p.m....
September 7, 2017
Synlogic Presents New Preclinical Data at International Congress of Inborn Errors of Metabolism
Data support the lead clinical program in urea cycle disorders (UCD) and the further development of Synthetic Biotic™ candidates as potential treatments for phenylketonuria (PKU) and maple syrup urine disease (MSUD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep....
September 1, 2017
Synlogic to Webcast Presentation at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2017-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan , M.B., B.Ch., will present a company overview at BioCentury’s 24 th Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017 , at 10:00...
August 28, 2017
Synlogic Completes Merger with Mirna Therapeutics
- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell , Ph.D., and Richard Shea CAMBRIDGE,...
June 26, 2017
Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020
– Novel Synthetic Biotic™ medicine, SYNB1020, under development for the treatment of hyperammonemia due to urea cycle disorders – CAMBRIDGE, Mass–( BUSINESS WIRE )–Synlogic™ has been granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate,...
June 19, 2017
Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines
Healthy volunteers study initiated for SYNB1020, a Synthetic Biotic™ medicine for the treatment of hyperammonemia                                                    ...
Displaying 85 - 96 of 115